{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:40:08Z","timestamp":1750538408726,"version":"3.41.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In recent years, a large number of articles have described the endocrine-related adverse events associated with immune checkpoint inhibitors, especially affecting the thyroid. A 37-year-old man affected by nasopharyngeal carcinoma (stage IVb) underwent serial <jats:sup>18<\/jats:sup>F-FDG PET\/CT evaluations during treatment with nivolumab (480 mg every 4 weeks) after first-line chemoradiotherapy. The patient had no history of thyroid disease and before starting immunotherapy the thyroid-stimulating hormone value was normal at 0.9 mU\/L (reference range, 0.27\u20134.2 mIU\/L). FDG PET\/CT studies revealed involution of the thyroid gland following immune checkpoint inhibitor\u2013induced thyroiditis.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003946","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T06:02:21Z","timestamp":1635141741000},"page":"253-254","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["An Evanishing Thyroid During Immune Checkpoint Inhibitor Therapy"],"prefix":"10.1097","volume":"47","author":[{"given":"Marco","family":"Cuzzocrea","sequence":"first","affiliation":[{"name":"Competence Centre for Thyroid Diseases\u2013Clinic for Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Paone","sequence":"additional","affiliation":[{"name":"Competence Centre for Thyroid Diseases\u2013Clinic for Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Ceriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Giovanella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","article-title":"Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)","volume":"42","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","year":"2019","journal-title":"Horm Metab Res"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s42000-020-00178-x","article-title":"Detection of thyroiditis on PET\/CT imaging: a systematic review","volume":"19","year":"2020","journal-title":"Hormones (Athens)"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","article-title":"Predicting response to immunotherapy by evaluating tumors, lymphoid cell\u2013rich organs, and immune-related adverse events using FDG-PET\/CT","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"journal-title":"Eur Urol Focus","article-title":"Incidence and clinical impact of inflammatory fluorodeoxyglucose positron emission tomography uptake after neoadjuvant pembrolizumab in patients with organ-confined bladder cancer undergoing radical cystectomy [published online November 7, 2020]","year":"2020","key":"bib5-20250621"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor\u2013induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","year":"2020","journal-title":"Thyroid"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1055\/a-1108-1934","article-title":"Thyroid atrophy and pancreatic involution after cancer immunotherapy","volume":"192","year":"2020","journal-title":"Rofo"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1089\/thy.2018.0418","article-title":"Histology of nivolumab-induced thyroiditis","volume":"28","year":"2018","journal-title":"Thyroid"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:07:05Z","timestamp":1750536425000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003946","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}